Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Adedayo A,Onitilo

第一单位： Department of Hematology and Oncology, Marshfield Clinic, Weston, Wisconsin, USA and Clinical Epidemiology Unit, School of Population Health, University of Queensland, Brisbane, Australia.

作者： Adedayo A,Onitilo ^[1] ; Jill K,Onesti ^[2] ; Richard M,Single ^[3] ; Jessica M,Engel ^[4] ; Ted A,James ^[5] ; Erin J,Aiello Bowles ^[6] ; Heather,Spencer Feigelson ^[7] ; Tom,Barney ^[8] ; Laurence E,McCahill ^[8]

作者单位： Department of Hematology and Oncology, Marshfield Clinic, Weston, Wisconsin, USA and Clinical Epidemiology Unit, School of Population Health, University of Queensland, Brisbane, Australia. ^[1] Grand Rapids Medical Education Partners, Grand Rapids, Michigan, USA. ^[2] University of Vermont, Burlington, Vermont, United States of America. ^[3] Marshfield Clinic Cancer Care at St Michaels Hospital, Stevens Point, Wisconsin, United States of America. ^[4] University of Vermont College of Medicine, Burlington, Vermont, United States of America. ^[5] Group Health Research Institute, Seattle, Washington, United States of America. ^[6] Kaiser Permanente Colorado, Denver, Colorado, United States of America. ^[7] Van Andel Research Institute, Grand Rapids, Michigan, United States of America. ^[8]